Umuthi wesifo sikashukela ungathuthukisa izimpawu zesifo sikaParkinson
I-Lixisenatide, i-glucagon-like peptide-1 receptor agonist (GLP-1RA) yokwelapha isifo sikashukela, ibambezela i-dyskinesia ezigulini ezinesifo sika-Parkinson sokuqala, ngokusho kwemiphumela yokuhlolwa komtholampilo kwesigaba sesi-2 eshicilelwe ku-New England Journal of Medicine. NEJM) ngomhlaka-4 Ephreli 2024.
Ucwaningo, oluholwa yiSibhedlela saseNyuvesi yaseToulouse (eFrance), lwaqasha izifundo ze-156, ezihlukaniswe ngokulinganayo phakathi kweqembu lokwelapha i-lixisenatide kanye neqembu le-placebo.Abacwaningi balinganise umphumela womuthi besebenzisa isikolo se-Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPRS) Ingxenye III, amaphuzu aphezulu esikalini abonisa ukuphazamiseka okukhulu kakhulu kokunyakaza.Imiphumela yabonisa ukuthi ngenyanga ye-12, amaphuzu we-MDS-UPRSS ingxenye III yehle ngamaphuzu angu-0.04 (okubonisa ukuthuthukiswa okuncane) eqenjini le-lixisenatide futhi yanda ngamaphuzu angu-3.04 (okubonisa ukuwohloka kwesifo) eqenjini le-placebo.
Isihloko somhleli se-NEJM sangaleso sikhathi siphawule ukuthi, phezulu, le datha iphakamisa ukuthi i-lixisenatide ikuvimbele ngokuphelele ukubhebhetheka kwezimpawu zesifo sika-Parkinson esikhathini esiyizinyanga eziyi-12, kodwa lokhu kungase kube umbono onethemba ngokweqile.Zonke izikali ze-MDS-UPDRS, okuhlanganisa Ingxenye III, ziyizilinganiso eziyinhlanganisela ezihlanganisa izingxenye eziningi, futhi ukuthuthukiswa engxenyeni eyodwa kungase kumelane nokuwohloka kwenye.Ukwengeza, womabili amaqembu esilingo kungenzeka ahlomule nje ngokubamba iqhaza ocwaningweni lomtholampilo.Kodwa-ke, umehluko phakathi kwamaqembu amabili esilingo ubonakala ungokoqobo, futhi imiphumela isekela umphumela we-lixisenatide kuzimpawu zesifo sika-Parkinson kanye nenkambo yesifo esingase sibe khona.
Mayelana nokuphepha, amaphesenti angu-46 abantu abaphathwa nge-lixisenatide baba nesicanucanu kanye namaphesenti angu-13 aba nokuhlanza. ukuncishiswa komthamo kanye nezinye izindlela zokusiza kungabaluleka.
"Kulolu cwaningo, umehluko wezikolo ze-MDS-UPDRS wawubalulekile ngokwezibalo kodwa ube mncane ngemva kwezinyanga ezingu-12 zokwelashwa nge-lixisenatide. Ukubaluleka kwalokhu okutholakele akukhona kubukhulu boshintsho, kodwa kulokho okubonisayo."Umhleli oshiwo ngenhla uyabhala, "Ukukhathazeka okukhulu kweziguli eziningi ze-Parkinson akusona isimo sazo samanje, kodwa ukwesaba ukuqhubeka kwesifo. Uma i-lixisenatide ithuthukisa amaphuzu we-MDS-UPDRS ngamaphuzu amaningi we-3, khona-ke inani lokwelapha lomuthi lingase libe nomkhawulo ( Ngakolunye uhlangothi, uma ukusebenza kahle kwe-lixisenatide kunqwabelana, okwandisa amaphuzu ngamanye amaphoyinti ama-3 ngonyaka esikhathini esiyiminyaka emi-5 kuye kweyi-10 noma ngaphezulu, lokhu kungaba ukwelashwa okuguqula ngempela isinyathelo esilandelayo ngokusobala esokwenza izivivinyo ezithatha isikhathi eside."
Ithuthukiswe ngumkhiqizi wezidakamizwa waseFrance i-Sanofi (SNY.US), i-lixisenatide yagunyazwa yi-US Food and Drug Administration (FDA) ekwelapheni uhlobo lwesifo sikashukela sohlobo 2 ngo-2016, okuyenze yaba eyesi-5 ye-GLP-1RA ukuthi imakethwe emhlabeni jikelele. kusukela ekuhlolweni kwemitholampilo, ayisebenzi kahle ekwehliseni i-glucose njengozakwabo i-liraglutide ne-Exendin-4, futhi ukungena kwayo emakethe yase-US kufike ngemva kwesikhathi kuneyabo, okwenza kube nzima ngomkhiqizo ukuthola indawo.Ngo-2023, i-lixisenatide yahoxiswa emakethe yase-US.I-Sanofi ichaza ukuthi lokhu kwakungenxa yezizathu zezentengiso kunezinkinga zokuphepha noma ukusebenza ngempumelelo nomuthi.
Isifo sikaParkinson yisifo se-neurodegenerative esenzeka kakhulu kubantu abadala abaphakathi nabadala, esibonakala kakhulu ngokundindizela okuphumuzayo, ukuqina nokunyakaza okuhamba kancane, okunembangela engakaziwa.Njengamanje, insika yokwelapha isifo sika-Parkinson iwukwelapha esikhundleni se-dopaminergic, okusebenza ngokuyinhloko ukuze kuthuthukiswe izimpawu futhi angenabo ubufakazi obuqand’ ikhanda bokuthinta ukuqhubeka kwesifo.
Izifundo ezimbalwa ezedlule zithole ukuthi ama-agonists e-GLP-1 receptor anciphisa ukuvuvukala kobuchopho.I-Neuroinflammation iholela ekulahlekeni okuqhubekayo kwamangqamuzana obuchopho akhiqiza i-dopamine, isici esiyinhloko se-pathological yesifo sika-Parkinson.Kodwa-ke, kuphela ama-agonists e-GLP-1 receptor afinyelela ebuchosheni asebenza ngempumelelo ku-Parkinson's disease, futhi muva nje i-semaglutide ne-liraglutide, ezaziwa kakhulu ngemiphumela yazo yokuncipha kwesisindo, azizange zibonise amandla okwelapha isifo sika-Parkinson.
Ngaphambilini, ukuhlola okwenziwa ithimba labacwaningi e-Institute of Neurology e-University of London (UK) kwathola ukuthi i-exenatide, ehlelwe ngendlela efana ne-lixisenatide, yenza ngcono izimpawu zesifo sikaParkinson.Imiphumela yocwaningo ibonise ukuthi emasontweni angu-60, iziguli eziphathwe nge-exenatide zinephuzu eli-1 lokunciphisa amaphuzu azo we-MDS-UPRSS, kuyilapho labo abaphathwa nge-placebo babe nokuthuthukiswa kwamaphuzu angu-2.1.Ihlanganiswe ngu-Eli Lilly (LLY.US), inkampani enkulu yase-US eyenza imithi, i-exenatide iyi-agonist yokuqala emhlabeni ye-GLP-1 receptor, eyayilawula imakethe iminyaka emihlanu.
Ngokwezibalo, okungenani ama-agonists ama-GLP-1 receptor ayisithupha ahloliwe noma okwamanje asahlolwa ukusebenza kwawo ekwelapheni isifo sika-Parkinson.
Ngokusho kweWorld Parkinson's Association, njengamanje kuneziguli ezinesifo sikaParkinson eziyizigidi ezi-5.7 emhlabeni wonke, kanti zilinganiselwa ezigidini ezi-2.7 eChina.Ngo-2030, i-China izoba nengxenye yenani labantu baseParkinson emhlabeni.Imakethe yomhlaba wonke yezidakamizwa ze-Parkinson izodayiswa ngama-RMB 38.2 billion ngo-2023 futhi kulindeleke ukuthi ifinyelele ku-RMB 61.24 billion ngo-2030, ngokusho kwe-DIResaerch (DIResaerch).
Isikhathi sokuthumela: Apr-24-2024
.png)
